After a median overall follow-up of 8.7 months , median OS was 13.1 months and 11.8 months for sunitinib and placebo , respectively ( hazard ratio [ HR ] , 0.914 ; 95 % CI , 0.762 to 1.097 ; stratified log-rank test , P = .168 ) .